Inferra AI / Company / ALKS

Alkermes Plc.

ALKS · Health Care

Last earnings Jul 28, 2026

Key results

Revenuequarter

$390.7 Million

Revenues of $390.7 Million &#x2014

SEC original ↗Alkermes Plc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

GAAP net incomequarter

$87.1 Million

GAAP Net Income of $87.1 Million and

SEC original ↗Alkermes Plc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

Diluted EPSquarter

$0.52

Diluted GAAP Earnings per Share of $0.52 &#x2014

SEC original ↗Alkermes Plc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

• Revenues and total prescriptions for the quarter grew 18% and 22%, respectively, compared to the second quarter of 2024.

SEC original ↗Alkermes Plc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

ARISTADA i • Revenues for the quarter were $101.3 million.

SEC original ↗Alkermes Plc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

• Revenues for the quarter grew 18% compared to the second quarter of 2024.

SEC original ↗Alkermes Plc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

ARISTADA revenuequarter

$11.0 million

• During the quarter, the company recorded ARISTADA revenue of approximately $11.0 million related to gross-to-net favorability, primarily driven by Medicaid utilization adjustments.

SEC original ↗Alkermes Plc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

VIVITROL • Revenues for the quarter were $121.7 million.

SEC original ↗Alkermes Plc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

Research and developmentquarter

$77,370 thousand

Research and development 77,370 59,649

SEC original ↗Alkermes Plc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

Selling, general, and administrativequarter

$170,849 thousand

Selling, general and administrative 170,849 168,113

SEC original ↗Alkermes Plc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

Operating incomequarter

$92,978 thousand

Operating Income 92,978 109,883

SEC original ↗Alkermes Plc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

AI analysis

Q2 2025 · reported Jul 29, 2025

Based on: Earnings release + Q2 2025 deck + parent 8-K — transcript not held

Revenue · Q2 2025

$390.7M

EX-99 · Jul 29, 2025

Diluted EPS · Q2 2025

$0.52

EX-99 · Jul 29, 2025

GAAP net income · Q2 2025

$87.1M

EX-99 · Jul 29, 2025

Operating income · Q2 2025

$92,978 thousand

EX-99 · Jul 29, 2025

Headline figures

Metric	Q2 2025	Prior qtr	Year ago
Revenue	$390.7 Million	—	—
GAAP net income	$87.1 Million	—	—
Diluted EPS	$0.52	—	—
ARISTADA revenue	$11.0 million	—	—
Research and development	$77,370 thousand	—	—
Selling, general, and administrative	$170,849 thousand	—	—
Operating income	$92,978 thousand	—	—

EX-99 · Jul 29, 2025

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

“Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation,” said Richard Pops, Chief Executive Officer of Alkermes

Based on: Earnings release + Q2 2025 deck + parent 8-K — transcript not held

Guidance & outlook

No guidance located in the held release

Risks & headwinds

The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk.

SEC original ↗Alkermes Plc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties.

SEC original ↗Alkermes Plc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

These risks and uncertainties include, among others: whether the company is able to achieve its financial expectations; clinical development activities may not be initiated or completed on expected timelines or at all; the results of the company’s development activities may not be positive, or predictive of future results 3 from such activities, results of future development activities or real-world results; the company’s products or product candidates could be shown to be ineffective or unsafe; the U.

SEC original ↗Alkermes Plc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks, assumptions and uncertainties.

SEC original ↗Alkermes Plc. — Presentation / slide deck (8-K exhibit)EX-99Jul 29, 2025

Documents

Earnings deck slides

0 decks with slide view

Alkermes Plc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors